Arcellx, Inc. (ACLX)
| Market Cap | 257.66M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -86.07M |
| Shares Out | 35.74M |
| EPS (ttm) | -145.55 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 45,530 |
| Open | 7.43 |
| Previous Close | 7.51 |
| Day's Range | 6.93 - 7.75 |
| 52-Week Range | 6.04 - 19.93 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 31.28 (+333.8%) |
| Earnings Date | Jun 23, 2022 |
About ACLX
Arcellx is a clinical-stage biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases. We believe cell therapies are one of the forward pillars of medicine, and our mission is to advance humanity by engineering cell therapies that are safer, more effective and more broadly accessible. Existing cell therapy solutions tend to be beneficial to a limited segment of patients, often result in high toxicity, and have narrow applicability in treatable indic...
Financial Performance
Financial StatementsAnalyst Forecast
According to 10 analysts, the average rating for ACLX stock is "Buy." The 12-month stock price forecast is 31.28, which is an increase of 333.84% from the latest price.
News
Arcellx Appoints Olivia Ware to Board of Directors
-- Replaces Lewis T. "Rusty" Williams, M.D.
Arcellx Provides Business Updates and Reports First Quarter 2022 Financial Results
-- First patient dosed in the Phase 1 clinical trial evaluating ACLX-001 utilizing groundbreaking ARC-SparX technology in relapsed or refractory multiple myeloma (r/r MM) -- -- Management to host live ...
Arcellx Announces Dosing of First Patient in its Phase 1 Clinical Trial Evaluating ACLX-001, the First Therapeutic in...
-- ARC-SparX is a novel CAR-T cell therapy treatment designed to allow for controllability and adaptability to potentially reduce toxicities associated with serious dose-limiting adverse events and over...
Arcellx Announces Publication in Blood Advances of Clinical Results from the Dose Escalation Cohorts of its CART-ddBC...
100% ORR; 75% CR/sCR; and evidence of durable clinical benefit in a population with poor prognostic features observed in the dose escalation cohorts with CART-ddBCMA FOSTER CITY, Calif. , May 9, 2022 /P...
Arcellx Announces Participation at the BofA Securities 2022 Healthcare Conference
FOSTER CITY, Calif. , May 5, 2022 /PRNewswire/ -- Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with c...
Arcellx to Present New Clinical Data from its CART-ddBCMA Phase 1 Trial in Patients with Relapsed or Refractory Multi...
-- Company to host a live webcast event with an expert panel of clinicians to discuss the clinical results on Sunday, June 5, 2022, at 7:00 PM CDT -- FOSTER CITY, Calif., April 27, 2022 /PRNewswire/ -- ...
Arcellx Presents Pre-Clinical Data for ACLX-002, a Novel CD123-targeted Universal CAR-T Cell Therapy for Relapsed or ...
-- ACLX-002 completely regresses multiple cell line and patient-derived AML xenografts -- -- Company plans to initiate ACLX-002 Phase 1 clinical trial in AML/MDS in 2H'22 -- FOSTER CITY, Calif., April 8...
Arcellx Provides Business Update and Reports Fourth Quarter and Year-End 2021 Financial Results
-- Completed upsized initial public offering of common stock, raising $142.3 million in gross proceeds including full exercise of underwriters' option to purchase additional shares -- -- Expanded compan...
Arcellx Announces Participation at the Barclays Global Healthcare Conference
FOSTER CITY, Calif., March 10, 2022 /PRNewswire/ -- Arcellx, Inc. (NASDAQ: ACLX), a clinical-stage cell therapy biotechnology company, announced today that chairman and chief executive officer, Rami Elg...
Arcellx Announces Pre-Clinical Data Presentation for ACLX-002, a Novel CD123-targeted Universal CAR-T Cell Therapy fo...
FOSTER CITY, Calif., March 8, 2022 /PRNewswire/ -- Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with ...
Arcellx Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters' Option to Purchase Add...
GAITHERSBURG, Md., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients wit...
CAR-T Player Arcellx Raises $123M Via Initial Public Offering, Opens Trading At $19
CAR-T company Arcellx Inc ACLX priced its IPO at $15 per share, raising $123.8 million at the low end of the Company's proposed range of $15 - $17. Get the Inside Access Traders Are Using to Profit More...
Arcellx Announces Pricing of Initial Public Offering
GAITHERSBURG, Md., Feb. 04, 2022 (GLOBE NEWSWIRE) -- Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients wit...
Arcellx sets IPO terms, looks to raise up to $140.3 million
Arcellx Inc. ACLX, has set terms for its initial public offering, in which the Maryland-based biotechnology company, which is developing cancer treatments, looks to raise up to $140.25 million. The comp...